Form 4: Stoke Therapeutics GC Allan Reports Stock Acquisition

Stoke Therapeutics General Counsel Jonathan Allan reported the acquisition of common stock through RSU vesting and an Employee Stock Purchase Plan.

Summary

• Jonathan Allan, General Counsel & Corp Sec of Stoke Therapeutics, Inc. (STOK), reported changes in his beneficial ownership of the company's common stock.
• On March 15, 2026, Allan acquired 7,475 shares of common stock through the vesting of Restricted Stock Units (RSUs) at an exercise price of $0.
• On the same date, he acquired an additional 6,000 shares of common stock from another RSU award, also at a $0 exercise price.
• A further 12,000 shares of common stock were acquired on March 15, 2026, from a third RSU award, with a $0 exercise price.
• The reported total beneficial ownership of common stock following these transactions is 37,731 shares.
• This total includes 425 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan (ESPP).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it reflects an executive's increased stake in the company, aligning their interests with long-term shareholder value, although it's a scheduled event rather than an open market purchase.

Positives

• Jonathan Allan, a key executive, increased his direct beneficial ownership of Stoke Therapeutics common stock to 37,731 shares.
• The acquisition of shares through RSU vesting and the Employee Stock Purchase Plan indicates continued participation and alignment of management interests with shareholders.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider acquisitions, particularly through the vesting of equity awards, are a routine aspect of executive compensation. While not an open market purchase, these transactions increase an executive's direct stake in the company, generally viewed as a positive for aligning management interests with shareholder value. This filing is a standard compliance report for such events.

Stakeholder Impact

• Shareholders: The increased beneficial ownership by a key executive enhances the alignment of management's financial interests with those of the shareholders.
• Employees: The existence of an Employee Stock Purchase Plan (ESPP) and Restricted Stock Units (RSUs) indicates a compensation structure designed to incentivize long-term commitment and performance across the company.

Next Steps

• Future vesting of remaining Restricted Stock Units on subsequent annual vesting dates, subject to the reporting person's continued service to the Issuer.

Key Dates

Recommendation

This Form 4 reports routine vesting of executive compensation and ESPP acquisitions, which are expected events and do not typically provide new fundamental information to warrant a change in investment recommendation. It confirms an executive's continued stake in the company.

Keywords

Stoke Therapeutics, STOK, Form 4, insider trading, beneficial ownership, RSU, Restricted Stock Units, Employee Stock Purchase Plan, ESPP, Jonathan Allan, General Counsel